Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results

References

• Anderson FA, Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007;82:777-82
   PubMed Web of Science ®Google Scholar
• Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 2016;137:3-10
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Venous thromboembolism: a public health concern. 2015. Atlanta, GA: CDCP
   Google Scholar
• Lefebvre P, Laliberté F, Nutescu EA, et al. All-cause and disease-related health care costs associated with recurrent venous thromboembolism. Thromb Haemost 2013;110:1288-97
   PubMed Web of Science ®Google Scholar
• Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298-310
   PubMed Web of Science ®Google Scholar
• Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006;21:23-9
   PubMed Web of Science ®Google Scholar
• Prandoni P. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1
   PubMed Web of Science ®Google Scholar
• Lin J, Lingohr-Smith M, Kwong WJ. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. Payer perspective. J Manag Care Pharm 2014;20:174-86
   PubMed Web of Science ®Google Scholar
• MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Heal Pharm 2006;63(20Suppl6):S5-15
   Web of Science ®Google Scholar
• Ghate SR, Biskupiak J, Ye X, et al. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm 2011;17:672-84
   PubMed Web of Science ®Google Scholar
• Bamber L, Muston D, McLeod E, et al. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. Thromb J 2015;13:20
   PubMed Web of Science ®Google Scholar
• XARELTO (rivaroxaban) tablets [prescribing information]. 2015. Titusville, NJ: Janssen Pharmaceuticals, Inc
   Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-25
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315-52
   PubMed Web of Science ®Google Scholar
• The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Once-daily oral direct factor Xa inhibitor rivaroxaban in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism. The Einstein-Extension study. ClinicalTrials.gov. 2014. Available at: https://clinicaltrials.gov/show/NCT00439725
   Google Scholar
• Wells PS, Prins MH, Levitan B, et al. Long-term anticoagulation with rivaroxaban for preventing recurrent VTE: a benefit-risk analysis of EINSTEIN-extension. Chest 2016;150:1059-68
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. Micromedex solution: Red Book online search results. Greenwood Village, CO: Truven Health Analytics; 2016. Available at: http://www.micromedexsolutions.com/
   Google Scholar
• Bookhart BK, Haskell L, Bamber L, et al. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. J Med Econ 2014;17:691-5
   PubMedGoogle Scholar
• Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86
   PubMed Web of Science ®Google Scholar
• LaMori JC, Shoheiber O, Mody SH, et al. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther 2015;37:62-70
   PubMed Web of Science ®Google Scholar
• Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73
   PubMedGoogle Scholar
• Miller JD, Ye X, Lenhart GM, et al. Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US. Clin Outcomes Res 2016;8:215-26
   PubMed Web of Science ®Google Scholar
• Casciano JP, Dotiwala Z, Kemp R, et al. Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspective. Am J Heal Pharm 2015;72:291-300
   PubMed Web of Science ®Google Scholar
• Piedade A, Paladini L, Tobaruella F, et al. Budget impact model (BIM) of rivaroxaban in comparison with enoxaparin plus warfarin in the treatment of venous thromboembolism (VTE) under the perspective of the private health system. Value Health 2015;18:A383-4
   PubMed Web of Science ®Google Scholar
• Kahler ZP, Beam DM, Kline JA. Cost of treating venous thromboembolism with heparin and warfarin versus home treatment with rivaroxaban. Acad Emerg Med 2015;22:796-802
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Coleman CI, Bookhart BK, et al. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. J Med Econ 2014;17:52-64
   PubMedGoogle Scholar
• Heisen M, Treur MJ, Heemstra HE, et al. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. J Med Econ 2017;20:813-24
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• Investigators TE. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Amin A, Jing Y, Trocio J, et al. Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. J Thromb Thrombolysis 2014;40:131-8
   Web of Science ®Google Scholar
• Coleman CI, Limone BL, Bookhart BK, et al. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. Thromb Res 2014;133:743-9
   PubMed Web of Science ®Google Scholar